Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma

International Journal of Laboratory Hematology

Volumn 32, Issue 6 PART 1, 2010, Pages

  Reid, S ^a   Yang, S ^b   Brown, R ^b   Kabani, K ^b   Aklilu, E ^b   Ho, P J ^b   Woodland, N ^a   Joshua, D ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CD138; CD38; Multiple myeloma; plasma cell

Indexed keywords

CD38 ANTIGEN; CD45 ANTIGEN; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DATA BASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIGENS, CD45; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS; RETROSPECTIVE STUDIES; SYNDECAN-1;

EID: 78349284733     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01222.x     Document Type: Article

References (25)

1. Al-Quran S., Yang L., Magill J., Braylan R., &, Douglas-Nikitin V., (2007) Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Human Pathology 38, 1779 - 1787.
2. Australian Incidence of Health and Welfare (2007) Australian Cancer Incidence and Mortality books - myeloma. Accessed March 21, 2009.
3. Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J., Moreau P., Amiot M., &, Pellat-Deceunynvk C., (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 91, 1234 - 1240.
4. Chen-Kiang S., (2005) Biology of plasma cells. Best Practice & Research: Clinical Haematology 18, 493 - 507.
5. DeVos J., Hose D., Reme T., Tarte R., Moreux J., Mahtouk K., Jourdan M., Goldschmindt H., Rossi J., Cremer F., &, Klein B., (2006) Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews 210, 86 - 104.
6. Dhodapkar M., Abe E., Theus A., Lacy M., Langford J., Barlogie B., &, Sanderson R., (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone cell differentiation. Blood 91, 2679 - 2688.
7. Griepp P., SanMiguel J., Durie B., Crowley J., Barlogie B., Blade J., Boccardo M., Child J., Avet-Loiseau H., Kyle R., Lahuerta J., Ludwig H., Morgan G., Powels R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., &, Westin J., (2005) International staging system for multiple myeloma. Journal of Clinical Oncology 23, 3412 - 3420.
8. Hoffbrand A., Moss P., &, Pettitt J., (2006) Essential Haematology 5th edn. Carlton, Blackwell Publishing Ltd.
9. Jaggannath S., (2008) Pathophysiological underpinnings of multiple myeloma progression. Journal of Managed Care Pharmacy 14, S7 - S11.
10. Joshua D., Peterson A., Brown R., Pope B., Snowdon L., &, Gibson J., (1996) The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. British Journal of Haematology 94, 76 - 81.
11. Jourdan M., Ferlin M., Legouffe E., Horvathova M.J.L., Rossi J., Wijdenes J., Brochier J., &, Klein B., (1998) The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. British Journal of Haematology 100, 637 - 646.
12. Kindt T., Goldsby R., &, Osborne B., (2006) Kuby Immunology. 6th edn. New York, Freeman and Company.
13. Kyle R., &, Rajukumar S., (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3 - 9.
14. Kyle R., Gertz M., Witzig T., Lust J., Lacy M., Dispenzieri A., Fonesca R., Rajkumar S., Offord J., Larson D., Plevack M., Therneau T., &, Greipp P., (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings 78, 21 - 33.
15. Landgren O., Kyle R., Pfeiffer R., Katzmann J., Caporaso N., Hayes R., Dispenzieri A., Kumar S., Clark R., Baris D., Hoover R., &, Rajkumar S., (2009) Monoclonal gammopathy of undetermined significance precedes multiple myeloma: a prospective study. Blood 113, 5412 - 5417.
16. Lima M., Fonseca S., Goncalves C., Guerra M., Queiros M., Santos A., Coutinho A., Pinho L., Marques L., Cunha M., Ribeiro P., Xavier L., Vieira H., Pinto P., &, Justica B., (2000) Immunophenotypic aberrations, DNA content and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells, Molecules and Disease 26, 634 - 645.
17. Van Marion A., Lokhurst H., &, Van Den Tweel J., (2003) Pathology of multiple myeloma. Current Diagnostic Pathology 9, 322 - 337.
18. Matsui W., Huff C., Wang Q., Malehorn M., Barber J., Tanhehco Y., Smith B., Civin C., &, Jones R., (2004) Characterisation of clonogenic multiple myeloma cells. Blood 103, 2332 - 2336.
19. Pope B., Brown R., Gibson J., &, Joshua D., (1999) The bone marrow plasma cell labelling index by flow cytometry. Cytometry (Communications in Clinical Cytometry) 38, 286 - 292.
20. Pope B., Brown R., Gibson J., Yuen E., &, Joshua D., (2000) B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance and implications for tumour therapy. Blood 96, 1274 - 1279.
21. Robillard N., Pellat-Deceunynvk C., &, Bataille R., (2005) Phenotypic characterisation of the human myeloma cell growth fraction. Blood 105, 4845 - 4848.
22. San Miguel J., Garcia-Sanz R., Gonzalez M., &, Orfao A., (1996) DNA cell content studies in multiple myeloma. Leukemia and Lymphoma 23, 33 - 41.
23. Tarlinton D., Radbruch A., Hiepe F., &, Dorner T., (2008) Plasma cell differentiation and survival. Current Opinion in Immunology 20, 162 - 169.
24. Witzig T., Kimlinger T., Stenson M., &, Therneaip T., (1998) Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukaemia. Leukemia and Lymphoma 31, 167 - 175.
25. Zhan F., Huang Y., Colla S., Stewart J., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burlington B., Anaissia E., Holimig K., Pineda-Roman M., Tricot G., VanRhee F., Walker R., Zangari M., Crowley J., Barber J., &, Shaughnessy J., (2006) The molecular classification of multiple myeloma. Blood 108, 2020 - 2028.